As CEO and co-founder of Innexo, Dominique van Gruisen leads considered one of Europe’s most superior hashish analysis and growth amenities, the place cultivation science meets pharmaceutical precision. Innexo is a Dutch hashish contract analysis group that designs and conducts cultivation and know-how trials for shoppers throughout the hashish sector, serving to corporations take a look at improvements beneath managed, data-rich situations.
His spectacular profession in hashish spans 20 years and encompasses Belgian affected person advocacy and clinician networks, in addition to European biotech lobbying and cultivation consulting on either side of the Atlantic. Van Gruisen’s aim is formidable: to take hashish past cultivation and right into a world of validated information, reproducible genetics and true pharmaceutical reliability, which calls for consistency. So, how do you do this?
Primarily based in Meterik, a village in The Netherlands, Innexo is conducting unbiased trials on lighting, vitamins and genetics in an effort to generate measurable, reproducible information that brings cultivation nearer to pharmaceutical requirements. And thru some key partnerships, they’ve give you some profound methods. The analysis middle is at present working with Las Vegas-based lighting firm Fohse, analyzing how precision lighting from their Cobra LED system impacts plant construction, cannabinoid expression and vitality effectivity.
“We’re utilizing the Cobra Execs, and shortly we’ll have tunable-spectrum fashions from Fohse,” van Gruisen says. “They’ve sensors that consistently learn the pure gentle within the greenhouse and alter routinely. If we will work with a dynamic spectrum that mirrors the solar, we will replicate the identical situations wherever on Earth, in any season.”
The examine benchmarks a variety of metrics—from cannabinoid and terpene expression to morphology and vitality use—to quantify how gentle impacts consistency. “Their system fills your stack with information,” van Gruisen says. “That’s what we’re after: info that lets us construct validated cultivation fashions moderately than assumptions.”
Lighting defines the atmosphere; genetics outline the inspiration. To deal with that, Innexo partnered with sister corporations Innoveins Seed Options and SeQso to develop—look forward to it—the world’s first AI-driven seed-sorting system for hashish.
“They gather the spectral information of every seed in a non-destructive method,” van Gruisen says. “Then they develop that seed, report its traits, feed these traits again into the system and the algorithm learns which spectral patterns predict which plant traits.”
When he first heard of the know-how, van Gruisen says, “I actually pulled my automobile over to name folks.” Exams confirmed it labored for hashish, opening the door to non-destructive quality-control certification on the seed stage. “If there’s one thing you’ll be able to distinguish, you’ll be able to design a seed-sorting algorithm and push a batch by way of to separate the great from the unhealthy,” he says.
The implications of this know-how stretch past yield. AI evaluation can detect pathogens equivalent to hop latent viroid and certify genetic high quality earlier than cultivation begins. “Corporations are growing F1 hybrids—stabilized strains,” van Gruisen says. “By scanning the seeds, you’ll be able to fine-tune even additional so your beginning materials is as strong as it may be.”
Van Gruisen believes AI-based seed fingerprinting might additionally scale back the business’s dependence on cloning. “Even while you use clones, you continue to discover large deviations in secondary metabolites relying on the season or humidity,” he says. “It’s very tough to supply a constant product in flower type.” Regulatory frameworks, he notes, demand pharmaceutical precision.
“When regulators say hashish must be a drugs, they imply it needs to be 98 to 102 p.c in step with what’s on the label,” he says. “That’s virtually unimaginable with a pure product. However with stable F1 hybrid genetics that begin from seed, you add one other quality-control checkpoint.”
For cultivators, F1 seeds supply cleaner begins, decrease prices and simpler scalability. For sufferers, they promise reliability—the identical genetics, the identical aid—each time.
Van Gruisen describes Innexo as a hyperlink between two sectors that hardly ever converse the identical language. “Growers discuss in grams per sq. meter,” he says. “Pharma talks in validated datasets and deviation tolerances. We sit within the center, making these conversations attainable.”
That bridge extends past know-how. Innexo can be reviving iconic legacy hashish genetics—long-flowering, terpene-rich cultivars—and reintroducing them by way of superior lighting and AI-guided cultivation. He goals to proper a few of the wrongs the business has made. “We took plenty of flawed turns with hashish within the final 20 years,” he says. “It’s time to rediscover what made this plant helpful within the first place and do it with correct science.”
